What We Mean By
“Science-Based”

If you found this page because you typed something like “mold illness not getting better” or “my doctor doesn’t believe me about mold” or “is there any actual science on mold treatment” — we need you to know something before you read another word:

You are not anxious. You are not a hypochondriac. You are not “just stressed.” You are sick, the evidence base for what’s making you sick is real and growing, and the reason you can’t find consistent, actionable, science-based information about it is not because the information doesn’t exist. It’s because the way science works — the way it gets funded, studied, published, and eventually filtered down to your doctor’s desk — is messier, slower, and more economically motivated than anyone is supposed to say out loud.

We’re going to say it out loud.

Not in a tinfoil-hat way. In a here are the documented facts about how research funding and publication bias work, with citations way. Because you deserve to understand the landscape you’re navigating. And because once you understand it, you can read any piece of health information — including ours — with the critical eye it deserves.

This piece is about what we mean when we say SirenMold is “science-based.” That’s a bigger conversation than it sounds like.

One more thing before we start: we’re going to teach you how to think about this, not what to think. That’s the whole point. By the end of this, you should be able to pick up any paper, any protocol, any claim on any health website — including this one — and evaluate it yourself. That’s what being science-based actually looks like in practice.

First: What Does “Science-Based” Even Mean?

Notice what that definition does not say. It doesn’t say “a science-based approach only uses randomized controlled trials.” It doesn’t say “a science-based approach ignores something unless Pfizer paid for the study.” It doesn’t say “a science-based approach dismisses what patients report about their own bodies.”

Those are popular misconceptions. They’re also, when you dig into them, not how science actually works.

And here’s what the phrase almost never includes, but should: a science-based approach is honest about uncertainty. It doesn’t dress up animal studies as human clinical evidence. It doesn’t call something “proven” when what actually exists is mechanistic support. It doesn’t pretend the absence of a study is the same as evidence of absence — and it doesn’t pretend the presence of a study is the same as truth.

That distinction — absence of evidence versus evidence of absence — is one of the most important things you’ll take away from this page. Let’s talk about how science actually works.

The Hierarchy of Evidence (and Why People Misuse It)

You’ve probably seen the phrase “evidence-based medicine” thrown around, sometimes as a compliment, sometimes as a way to shut down a conversation. (“That’s not evidence-based.” Translation: stop asking questions and take the prescription.) What it actually refers to is a real framework for evaluating different types of research based on their reliability.

Here’s the hierarchy, simplified:

Now here’s what the textbooks sometimes leave out: the hierarchy exists to help us evaluate confidence levels, not to establish what’s worth knowing. A strong mechanism demonstrated in cell cultures is worth knowing. A well-documented pattern across hundreds of patient reports is worth knowing. A compound that has been used safely by humans for four thousand years is worth knowing, even if nobody has run an RCT on it.

Think of the evidence hierarchy like a jury system. A murder conviction requires a high bar of evidence. But that doesn’t mean eyewitness testimony, security footage, and a suspect’s own prior statements are worthless — it means they need to be weighed carefully against each other, with their limitations understood. You wouldn’t acquit a murderer just because you didn’t have a signed confession.

Similarly, you wouldn’t dismiss activated charcoal as a mycotoxin binder just because there isn’t a double-blind RCT funded by a pharmaceutical company studying its use in mold toxicity patients specifically. Activated charcoal has been binding toxins in the human gut for centuries. The mechanism is documented. The safety profile is extraordinarily well-established. Calling it “unproven” because it lacks a certain type of study is like saying we can’t be sure the sun rises every morning because we haven’t run an RCT on it.

The Part Nobody Tells You: Who Pays for the Science

Here’s the uncomfortable structural reality of how clinical research gets funded, published, and eventually ends up in your doctor’s treatment guidelines.

Research is expensive. A proper randomized controlled trial for a therapeutic intervention can cost tens to hundreds of millions of dollars. Somebody has to pay for that. And the people with the money to pay for it — pharmaceutical companies — are the same people who profit from the results.

That’s not a conspiracy theory. That’s a documented economic structure.

A systematic review published in the British Medical Journal found that research funded by pharmaceutical companies was significantly more likely to report outcomes favorable to the sponsor’s product than research funded from other sources. A meta-analysis in the Cochrane database, one of the most rigorous evidence-review bodies in medicine, found that industry-funded clinical trials had roughly a 27% higher risk of producing favorable efficacy results compared to independently funded trials.

Note carefully: this wasn’t explained by methodological differences. Industry-funded trials were sometimes better designed in terms of blinding and procedure. The bias emerged through other channels — what questions got asked, what comparators were chosen, which results got published, and which got quietly filed away.

That last part — the filing-away — has its own name: publication bias. If a company runs ten studies on a drug and eight of them show it doesn’t work, those eight studies are under no legal obligation to be published. The two that showed positive results might be. The published literature then reflects two studies suggesting the drug works, with zero context for the eight that suggested otherwise.

This is documented. This is not disputed by serious researchers. It’s why ClinicalTrials.gov exists — to register studies before they’re run so that negative results can be tracked and accounted for.

We’re telling you this not to make you distrust all science. We’re telling you so you understand one of the key reasons why garlic doesn’t have as many randomized controlled trials as itraconazole. And more broadly, so you understand why mold illness treatment — complex, chronic, multi-system, and almost impossible to monetize with a single patentable compound — has so few large trials at all. Chronic, multi-variable illnesses don’t fit neatly into the clean experimental models that generate publishable RCTs. That’s not a conspiracy. That’s a structural mismatch between how research works and how illness actually presents.

The Patent Problem: Why “No Study” Doesn’t Mean “Doesn’t Work”

This is the part that, once you understand it, you will see everywhere.

Drug development requires massive investment. That investment is only rational if the developing company can recoup it through exclusive sales rights — a patent. Patents last roughly twenty years from filing, which means a pharmaceutical company that develops, tests, and brings a drug to market might have five to ten years of exclusivity before generics appear. The economics require that the drug generates enough revenue in that window to justify the R&D cost.

Natural compounds — garlic, berberine, activated charcoal, allicin, quercetin — cannot be patented in their natural form. You cannot own the rights to garlic. So no pharmaceutical company has a financial incentive to spend fifty million dollars proving that garlic works for your condition, because even if they proved it beyond any doubt, they couldn’t prevent every grocery store and supplement brand from selling it the next day.

This is why the evidence landscape looks the way it does. Itraconazole — a patentable pharmaceutical antifungal — has extensive clinical trial data. Allicin — the bioactive compound in garlic that demonstrably inhibits Aspergillus fungal growth in laboratory studies, in animal models, and across decades of research — has a fraction of that data, despite showing genuine efficacy and an excellent safety profile.

Does this mean allicin is better than itraconazole? Not necessarily. Does it mean allicin is worse, or that the evidence doesn’t exist? Also no. It means the evidence that does exist — and it’s real, published peer-reviewed research (Shadkchan et al., Journal of Antimicrobial Chemotherapy, 2004, doi:10.1093/jac/dkh174; multiple studies via PubMed PMC352060 and others) — needs to be read with the understanding that the absence of large Phase III clinical trials is an economic artifact, not a scientific verdict.

Reasoning Through It: A Framework

This is a good moment to introduce something we’ll use throughout this site. When evaluating any intervention — pharmaceutical or natural, studied extensively or barely at all — we find it useful to run it through these six questions:

Running any intervention through these questions doesn’t give you a definitive answer. It gives you a structured way to think about what you’re considering, which is infinitely more useful than either reflexive acceptance or reflexive dismissal.

Reasoning in Action: Activated Charcoal vs. Cholestyramine

The same activated charcoal vs. cholestyramine comparison mentioned above is worth walking through in full because it illustrates exactly how to reason through a decision without relying on marketing, protocols, or authority.

Both are mycotoxin binders. Both work by the same general mechanism: binding toxin-laden bile in the gut so it exits via stool rather than recirculating through the body. Both are used in mold toxicity and mycotoxin detox protocols.

Here’s how the comparison actually looks across our six questions:

The conclusion: This is not a case where one option is scientifically validated and the other is folk medicine. Both have evidence. Both work. The comparison looks the way it does because one option was profitable to study more extensively — not because the other doesn’t work.

We say this as an observation, not an indictment. Understanding incentive structures is not the same as claiming malice. It just means you need to factor those structures into how you weigh the evidence in front of you.

Millennia of Human Use Is Also Data

Here’s something worth sitting with: the most extensive human trial ever run on any substance is human history.

Garlic has been used medicinally for at least four thousand years. We have documented use in ancient Egypt, Greece, Rome, China, and India, including specific antimicrobial applications. When modern researchers eventually isolated allicin and tested it in labs, they found that the mechanism behind why garlic had been used this way for millennia was exactly what the ancient observations suggested. Inhibition of fungal cell membranes. Broad-spectrum antimicrobial activity. Anti-inflammatory and immunomodulatory effects.

Activated charcoal has been used to bind toxins since at least 1550 BCE, documented in Egyptian medical papyri. The Romans used it for gastrointestinal complaints. Modern emergency medicine uses it for acute poisoning cases today. The mechanism — a porous carbon surface that physically adsorbs a remarkably broad range of molecules — is well understood and hasn’t changed.

This isn’t anecdote. This is longitudinal observational data at a scale that no RCT will ever match. The sample size is “every human who ever lived who used this thing and survived to report on it.” The limitation is obvious: it’s not controlled, it’s not blinded, and causality is impossible to establish cleanly. But “safe for human use” is a question that four thousand years of continuous use answers with a reasonable degree of confidence.

Is it even better when we understand exactly why it works? Yes. Very. The discovery of allicin’s specific mechanism of action — how it disrupts fungal cell membranes at the molecular level, why it’s effective against Aspergillus at measurable concentrations — is genuinely fascinating science that makes the traditional use make complete sense. We love peer-reviewed research. We love it even more when it validates what human experience already suspected. That’s not woo. That’s scientific confirmation of an observation that was already pretty solid evidence.

What “Bro Science” Gets Right and Wrong

Let’s talk about a phenomenon you’ve probably already encountered if you’re in any mold illness community online: bro science.

Bro science is the informal transmission of health information through personal experience, community forums, and the kind of collective experimentation that happens when a lot of sick people are sharing notes because their doctors have run out of answers. It sounds dismissive to call it that, and in some contexts it can be. But let’s be honest about what it actually is: it’s N-of-many observational data, self-collected, with all the limitations that implies — no control groups, no blinding, massive selection bias — and it’s also the reason some genuinely useful approaches get discovered before the clinical research catches up.

People in mold illness communities have been talking about the importance of mitochondrial support in mold toxicity recovery for years before the mechanistic research connecting mycotoxin exposure to mitochondrial membrane disruption was widely published. People were using berberine as a natural antifungal based on community experience long before researchers began characterizing its specific mechanisms against fungal biofilms.

The risk of bro science is obvious: people extrapolate from their own experience to everyone else’s, post dosing recommendations with confidence they haven’t earned, and sometimes get things importantly wrong. Someone’s “this cured me” is not a treatment protocol for your different genetics, different fungal species, different disease severity, different comorbidities.

The value of bro science, properly understood, is also real: it generates hypotheses. It surfaces patterns. It points researchers toward what’s worth studying. It keeps seriously ill people alive while the formal research catches up. And when it’s collected systematically — as patient-reported outcomes, as case reports, as observational data — it has genuine scientific value.

How to Use Community Information Without Getting Hurt

This is important enough to be explicit about, because the line between “sharing experience” and “prescribing to strangers on the internet” is one that matters — for your safety and legally.

What’s appropriate in community spaces:

What’s not appropriate, and why:

The reason for these lines isn’t bureaucratic. It’s because what worked for someone at a certain disease stage, with certain genetics, in certain circumstances may be actively harmful to someone at a different stage, with different genetics, in different circumstances. Invasive aspergillosis in someone with a history of liver disease is a fundamentally different situation than in someone without. MCAS changes how your body responds to almost everything. EDS changes the tissue context entirely.

The most useful community data is specific, honest, and framed correctly. “I have hEDS and MCAS. At week three of low-dose allicin, I had a significant histamine flare that required intervention. Here’s what helped.” That’s valuable. “Allicin causes histamine flares, don’t take it” is not, because it’s a universal claim drawn from one person’s individual experience.

On Self-Reported Data: Why Your Experience Counts

There’s a formal concept in modern medicine called Patient-Reported Outcomes (PROs). These are systematic measures of how patients actually feel — fatigue, cognitive function, pain, quality of life — as opposed to what a lab value or imaging study shows. PROs are increasingly recognized by the FDA and EMA as legitimate endpoints in clinical trials, because they capture something biomarkers can’t: whether the treatment is actually helping the person.

There’s a related concept gaining traction called Real World Evidence (RWE) — data generated from actual clinical practice and patient experience outside of controlled trials. The FDA has guidance documents on incorporating RWE into regulatory decisions. It’s not a fringe idea. It’s an emerging legitimate research framework.

We treat every self-reported experience on SirenMold as a legitimate data point from a trustworthy source, with two important caveats:

The experience is real. The explanation may not be. If you felt better after starting something, you felt better. We believe you completely. The explanation for why you felt better — what mechanism was responsible, whether it was the thing you started or something else you changed simultaneously, whether the timing was coincidental — is a separate question that requires more investigation.

The experience is yours. It may not generalize. What happened in your specific body, at your specific disease stage, with your specific genetics and comorbidities, may or may not apply to someone else. This isn’t about doubting you. It’s about honesty regarding the limits of individual data points.

What we want to build here, over time, is the ability to look across many individual reports and find patterns — especially when people report similar experiences under similar conditions. That kind of pattern, even without controlled trials, generates real hypotheses worth investigating. It’s how some of the most important clinical observations in medicine began.

If you post in the forum that you started d-ribose and your walking distance improved from fifty feet to two hundred feet over twenty-eight days, we’re going to treat that as a real observation from a reliable witness to your own experience.

We’re NOT going to tell you that your perception is invalid or that you imagined it.

We’re going to note that n=1 is the beginning of a hypothesis, not the conclusion of a clinical trial. We’re going to point you to the mechanistic research that might explain why that happened. We’re going to make sure everyone understands that your experience is real in your specific body AND it is not automatically the experience another patient will have.

The person who will need to apply that information to their situation is each patient as an individual, with their doctor’s professional guidance.

How to Read a Scientific Paper (Even If You Never Have)

Many places fail to teach this in school. But if you’re navigating a serious illness, being able to evaluate a research paper — even at a basic level — is a survival skill.

Here’s a usable filter. When you encounter any study, any research claim, any “the science says” statement:

Start with the funding. Check the “Funding” and “Conflicts of Interest” disclosures at the bottom of the paper. If the study was funded by the company whose drug it’s studying, factor that in. It doesn’t invalidate the study — it means you should weight independent replications more heavily, and look carefully at what comparator was used and what questions were asked.

Ask: what kind of study is this? In vitro (in a cell culture dish) means they showed a mechanism is possible. Animal study means they showed it works in a mouse or rat. Observational study means they noticed a pattern in real humans over time. RCT means they tested it in a controlled experiment with real humans. Each step is more informative for human clinical application, with different limitations. Don’t let anyone cite an in vitro study as if it proves an effect in living humans.

Ask: who was studied? Clinical trials often exclude the sickest patients, the oldest patients, patients with significant comorbidities, pregnant people, and many others. The population that gets studied in a clean trial is often not the population that most needs the treatment. If you have EDS, MCAS, are immunocompromised, or have multiple overlapping conditions, the chances that any given clinical trial population resembled your biology are relatively low.

Ask: what dose, and for how long? A study showing no effect at low doses tells you nothing about higher doses, and vice versa. A six-week trial tells you little about long-term outcomes. Duration and dosing are frequently underreported or underexplored, especially in studies of natural compounds.

Ask: what was actually measured? “Biomarker X improved” is not the same as “patients felt better and could function.” “No adverse events were reported” only means something if adverse events were being systematically tracked. A study can show statistically significant improvement in a lab value while participants felt no different. Look at what was measured and whether it connects to what you actually care about.

Understand what “statistically significant” does and doesn’t mean. Statistical significance means the result was unlikely to be due to chance, given the sample. It does not mean the effect was large, clinically meaningful, or guaranteed to apply to you. A study can find a statistically significant improvement that amounts to, in real life, something barely measurable. Ask about effect size, not just p-values.

And the hardest one: what wasn’t measured? Every study has a scope. Everything outside that scope is unknown, not proven absent. A study on whether Compound X affects Biomarker Y tells you nothing about whether it affects Biomarker Z, symptom experience, quality of life, or long-term outcomes — unless those were also measured.

The translation table you actually need:

You don’t need a PhD. You need curiosity and a willingness to slow down instead of accepting summary statements at face value. We’ll model this throughout the site — citing primary sources wherever we can, flagging the level of evidence, noting explicitly when we’re working from animal data, in vitro data, or extrapolation rather than human clinical trials.

The Right to Know — and the Right to Try

In 2018, the US federal government passed the Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act. It’s a law that allows terminally ill patients who have exhausted approved treatment options to access experimental drugs that have completed at least Phase I safety testing, bypassing some FDA approval requirements.

We’re not telling you this because invasive aspergillosis will necessarily qualify you under the law’s specific language — that’s a conversation for your doctor and your lawyer. We’re telling you this because the law’s existence reflects a principle that we think applies more broadly:

If you are healthy and considering a supplement to optimize your already-functional life, the bar for evidence should be high and the tolerance for uncertainty should be low. If you have been sick for years, have tried established protocols, are deteriorating, and are running out of options — the calculation looks different. You’re not choosing between “safe” and “risky.” You’re choosing between different categories of risk, one of which is essentially just laying down and dying.

The Right to Try Act embodies this recognition at a legal level. It says: for terminally ill patients who have run out of options, informed autonomy matters more than regulatory certainty.

We are extending that logic to an informational level. Not advocating recklessness — explicitly the opposite. But recognizing that if you’re very sick, you deserve access to the complete picture of what’s known and what’s uncertain, so you can make informed decisions with a healthcare provider who will engage with you honestly.

The law is explicit about informed consent. You have to understand what you’re deciding. The information has to be real. But the decision is yours.

That’s essentially the philosophy of this site, extended to a practical level. We’re not giving you medical advice or a protocol to follow. We’re giving you information — as complete, as rigorous, as honestly caveated as we can make it — so that you can walk into your doctor’s office with real questions, real citations, and a real basis for a real conversation.

If your life is on the line, you deserve complete information. Not simplified, dumbed-down information. Not information filtered through what’s most convenient for a commercial interest. Not information that stops at “there isn’t an RCT for that” as if that’s the end of the story. Complete information. With all its complexity and uncertainty honestly labeled.

What We Are Not Doing Here

This matters enough to be explicit.

We are not telling you what to do. We are not your doctor. We are not diagnosing you. Nothing on this site constitutes medical advice, and we mean that genuinely, not just legally.

We are also not telling you to abandon your doctor or your medical care. The most dangerous thing about a lot of mold illness communities online is the implicit (sometimes explicit) message that conventional medicine has failed you so you should go it alone. That’s not what we believe.

What we believe is that you need a healthcare provider who will work with you, take your experience seriously, and be willing to engage with evidence that might not fit neatly into the standard treatment algorithm. Finding that person, and bringing them good information, is half the battle. We’re here to help with the information.

Here’s how we’d describe our stance, as plainly as we can:

Open, but not gullible. We take all evidence seriously, including evidence from community experience and centuries of traditional use. We also maintain standards for what we claim to know versus what we hypothesize.

Skeptical, but not dismissive. We question funding sources, study design, and commercial incentives. We don’t use skepticism as a reason to ignore a patient’s reported experience or a compound’s plausible mechanism.

Structured, but flexible. We have standards. Those standards account for the reality that mold illness is complex, research is incomplete, and the people who need this information can’t always wait for the peer-reviewed literature to catch up.

How This Site Approaches Evidence: Our Standard

So: what do we actually mean when we say we’re science-based? Here’s our working standard, applied to everything we publish:

A Final Note

This site exists because of a specific experience: being very sick, having doctors who didn’t know what to do, finding an information landscape that was either medically inaccessible or commercially compromised, and deciding to build something better.

The case study at the center of this site documents an experience with invasive aspergillosis — one of the most severe forms of mold illness possible — and a treatment approach that prioritized restoring cellular energy production before anything else. Measurable improvement within twenty-eight days, in a situation where improvement wasn’t guaranteed.

We’re not telling you that story to give you hope at the expense of honesty. We’re telling it because it happened, we documented it carefully, and the pharmacological reasoning behind every decision has been laid out in full for any clinician who wants to evaluate it.

This site is for the patient at 3 AM who is scared and not getting better. It’s also for the naturopathic doctor who has a patient not responding to existing protocols and needs a different framework. It’s for the primary care physician who has never had training on mold illness and has a patient sitting in their office who desperately needs them to take it seriously.

For all of you: the science exists. It’s messier and more complicated than anyone advertises, but it’s real. You deserve to understand it on its own terms, with its limitations visible and its possibilities clear.

That’s what we mean by science-based.

That’s what we’re here to do.